Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules is a single capsule formulation that includes the antianxiety action of chlordiazepoxide hydrochloride and the anticholinergic/spasmolytic effects of clidinium bromide. Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsule contains 5 mg Chlordiazepoxide Hydrochloride and 2.5 mg clidinium bromide, along with lactose, pre-gelatinized starch, talc, titanium dioxide, and Black Ink SB-9041 (Shellac, Propylene Glycol, FDandC Blue #1 Aluminum Lake, FDandC Yellow #6 Aluminum Lake, FDandC Red #40 Aluminum Lake).
The FDA has classified this drug as 'possibly' effective for the following indications: For use as adjunctive bowel syndrome (irritable colon, spestic colon, mucous colitish) and acute enterocolltis. Final classification of the less-than-effective indications requires further investigation.
Clinical Trials Related to Chlordiazepoxide and Clidinium (Chlordiazepoxide / Clidinium)
Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal [Completed]
A randomized, double-blind controlled trial comparing treatment outcomes between
chloriazepide, or gabapentin to treat alcohol withdrawal syndrome in alcohol dependent
veteran subjects. The objective of this trial is to compare the safety and effectiveness of
these two medications. Intervention is a fixed dose taper of chlordiazepoxide, or gabapentin
over 6 days. Subjects will be evaluated for 7-10 days to monitor alcohol abstinence,
withdrawal severity scores, adverse events including ataxia, sedation, cognitive function
and alcohol craving.
Pioglitazone as an Adjunct for Moderate to Severe Depressive Disorder [Completed]
The purpose of this study is to determine whether Pioglitazone as an adjunct to Citalopram
is effective in treatment of moderate to severe depression
Outpatient Treatment of Alcohol Withdrawal Syndrome [Completed]
The purpose of this study is to compare a fixed-schedule therapy versus a symptom-triggered
therapy for alcohol withdrawal syndrome in medical outpatients.
- Self-governance in monitoring AWS (alcohol withdrawal syndrome) symptoms and medication
- Clinically controlled trial of two regimens for medical treatment of alcohol
- Outpatient treatment of alcohol withdrawal syndrome
A Study of the Use of Combination of Anti-cholinergic and Minor Tranquilliser in the Treatment of Non-cardiac Chest Pain - a Double Blind Placebo Controlled Study [Recruiting]
Non-cardiac chest pain is a common clinical problem encountered in our practice but at
present, the results of treatments are unsatisfactory. The pathogenesis remains unknown but
altered motility of the esophagus and psychological factors including anxiety have been
implicated as important factors. Reports of the single use of anticholinergic drugs and
anxiolytics have yielded conflicting results, has been demonstrated to yield marginal or of
no value. However the use of the combination therapy, especially with a double blind fashion
have not been reported. On that basis, we propose to use a combination of anti-cholinergic
and tranquilliser for the symptomatic treatment of non-cardiac chest pain. The aim of this
study is to evaluate the efficacy of combination therapy of anti-cholinergic and anxiolytic
drugs in the treatment of non-cardiac chest pain.
Page last updated: 2012-10-18